Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT

PHASE2CompletedINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2017

Conditions

Acute Myeloid LeukemiaAcute Lymphoid LeukemiaLymphomaMyelodysplastic SyndromesChronic Lymphocytic LeukemiaImmune System Diseases

Interventions

DRUG

Cyclophosphamide

DRUG

Busulfan

DRUG

Fludarabine monophosphate

DRUG

Tacrolimus

DRUG

Mycophenolate mofetil

PROCEDURE

Allogeneic hematopoietic stem cell transplantation

Trial Locations (1)

First Pavlov State Medical University of St. Petersburg, Saint Petersburg

All Listed Sponsors

lead

Ivan S Moiseev

OTHER

NCT02294552 - Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT | Biotech Hunter | Biotech Hunter